

Supplementary Table 1: ctDNA alterations detected

Alteration*	Number of times it was detected**
ESR1:pV392I	1
PIK3CA:pE542K	1
PIK3CA:pE545K	2
TP53:pR273H	2
TP53:pY220C	3
TP53:pR175H	1
ERBB2 amplification***	5

^{*}The PIK3CA mutations were detected by both the UltraSEEK and naica Crystal Digital PCR technologies

Supplementary Table 2: Summary of model performance corrected for optimism by leave one out cross validation including naive confidence intervals.

Model	Pre-treatment		On-treatment		Post-treatme	Post-treatment	
	AUC	MSE	AUC	MSE	AUC	MSE	
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	
	0.76	0.94	0.83	0.86	0.82	0.87	
Clinical-radiological	(0.62-0.88)	(0.63-1.33)	(0.71-0.93)	(0.60-1.16)	(0.71-0.92)	(0.61-1.18)	
Liquid biopsies	NA	NA	0.51 (0.34-0.67)	1.57 (1.22-1.98)	0.76 (0.63-0.88)	1.27 (1.00-1.60)	
MRI features	NA	NA	0.66 (0.51-0.81)	1.27 (0.92-1.66)	0.69 (0.53-0.81)	1.25 (0.93-1.60)	
Clinical-radiological + liquid	0.77	0.99	0.82	0.88	0.86	0.82	
biopsies	(0.64-0.88)	(0.63-1.42)	(0.71-0.92)	(0.58-1.18)	(0.76-0.94)	(0.54-1.12)	
Clinical-radiological +	0.77	0.99	0.82	0.88	0.83	0.89	
MRI features	(0.64-0.88)	(0.65-1.41)	(0.70-0.92)	(0.57-1.23)	(0.70-0.93)	(0.56-1.24)	
Liquid biopsies + MRI features	NA	NA	0.64 (0.47-0.78)	1.38 (1.01-1.83)	0.76 (0.64-0.88)	1.24 (0.92-1.57)	
Clinical-radiological + Liquid	0.76	1.03	0.81	0.91	0.86	0.84	
biopsies + MRI features	(0.63-0.88)	(0.67-1.46)	(0.70-0.91)	(0.59-1.25)	(0.75-0.94)	(0.56-1.16)	
•	0.76	0.94	0.76	0.94	0.76	0.94	
Only clinical	(0.62-0.87)	(0.62-1.36)	(0.62-0.87)	(0.62-1.36)	(0.62-0.87)	(0.62-1.36)	
	0.76	0.98	0.78	0.98	0.85	0.89	
Only clinical + liquid biopsies	(0.63-0.87)	(0.62, 1.42)	(0.65-0.88)	(0.67-1.39)	(0.74-0.94)	(0.58-1.29)	
	0.76	0.98	0.82	0.92	0.84	0.95	
Only clinical + MRI features	(0.63-0.87)	(0.63-1.39)	(0.71-0.91)	(0.57- 1.41)	(0.72-0.93)	(0.59- 1.42)	
Only clinical + MRI features +	0.76	1.01	0.81	0.97	0.85	0.91	
liquid biopsies	(0.63-0.87)	(0.65-1.43)	(0.70-0.91)	(0.62-1.45)	(0.74-0.93)	(0.57-1.35)	

CI = confidence interval, AUC = area under the receiver operating characteristic curve for predicting pCR (RCB 0), MSE = mean standard error, measures the average squared difference between the observed and predicted values. A lower value indicates a better fit of the model. NA = not applicable, no predictors remained in the model.

Supplementary Table 3: Coefficients of prediction models

Model	Predictor	Coefficient
Clinical-	(Intercept)	1.50
radiological pre-	IHC subtype ER-/HER2-	-0.76
treatment	IHC subtype ER+-/HER2+	-0.74
	Grade 3	-0.54
	Tumor size on baseline MRI	0
	Nodal status	0.89
	(Intercept)	0.84

^{**}None of the alterations were detected in more than one sample of the same patient

^{***} ERBB2 amplification was not found in all patients in HER2+ disease on IHC

Clinical-	IHC subtype ER-/HER2-	-0.56
radiological on-treatment	IHC subtype ER+-/HER2+	-0.58
on-treatment	Grade 3	-0.45
	Tumor size on baseline MRI	0
	Nodal status	0.71
	Relative change in tumor size on MRI 2	0.01
Clinical-	compared to baseline (Intercept)	0.83
radiological	IHC subtype ER-/HER2-	-0.54
post- treatment	IHC subtype ER+-/HER2+	-0.55
	Grade 3	-0.45
	Tumor size on baseline MRI	0
	Nodal status	0.70
	Relative change in tumor size on MRI 2	0.01
	compared to baseline Relative change in tumor size on MRI 3	0
	compared to baseline	Ŭ
Liquid biopsiesies	(Intercept)	1.25
pre-	Amplifiable copies	0
treatment	cfDNA integrity	0
	Methylation scores	0
	Mutations	0
	Plasma DNA concentration	0
MRI features	(Intercept)	1.25
pre- treatment	ADC	0
	Diameter	0
	Heterogeneity	0
	Kinetics	0
	Margin	0
	Shape	0
	T2	0
	Uptake	0
	Volume	0
Liquid	(Intercept)	0
biopsies on- treatment	Amplifiable copies	1.00
	cfDNA integrity	0
	Methylation scores	0
	Mutations	0
	Plasma DNA concentration	0
MRI features	(Intercept)	0.12
on-treatment	ADC	0
	Diameter	0

	Heterogeneity	0
	Kinetics	0
	Margin	0
	Shape	0
	T2	0
		0
	Uptake	
	Volume	0.90
Liquid biopsies post-	(Intercept)	-2.82
treatment	Amplifiable copies	1.15
	cfDNA integrity	0
	Methylation	2.10
	Mutations	0
	Plasma DNA concentration	0
MRI features	(Intercept)	-0.33
post- treatment	ADC	0
	Diameter	0.10
	Heterogeneity	0
	Kinetics	0
	Margin	0
	Shape	0
	T2	0.39
	Uptake	0
	Volume	0.78
Clinical-	(Intercept)	-0.15
radiological + liquid	Clinical-radiological model	1.12
biopsies pre-	Liquid biopsies model	0
treatment Clinical	(Intercept)	-0.15
radiological +	Clinical-radiological model	1.12
MRI features pre-	Computer extracted MRI features model	0
treatment	Computer extracted with readures model	
Clinical radiological +	(Intercept)	-0.15
LB + MRI	Clinical-radiological model	1.12
features pre- treatment	Liquid biopsies model	0
	Computer extracted MRI features model	0
Clinical	(Intercept)	-0.65
radiological + liquid	Clinical-radiological model	1.08
biopsies on- treatment	Liquid biopsies model	0.44
Clinical	(Intercept)	-0.50
radiological +	Clinical-radiological model	1.02
MRI features on-treatment	Computer extracted MRI features model	0.38
	para a sacrata mana a sacrata madel	

Liquid	(Intercept)	-0.91
biopsies +	Liquid biopsies model	0.62
MRI features on-treatment		
	Computer extracted MRI features model	1.11
Clinical radiological +	(Intercept)	-0.86
liquid	Clinical-radiological model	0.98
biopsies + MRI features	Liquid biopsies model	0.39
on-treatment	Computer extracted MRI features model	0.32
Clinical	(Intercept)	-0.67
radiological + liquid	Clinical-radiological model	0.98
biopsies post-	Liquid biopsies model	0.55
treatment Clinical	(Intercept)	-0.45
radiological +	Clinical-radiological model	1.03
MRI features post-	Computer extracted MRI features model	0.33
treatment	Computer extracted with features model	0.55
Liquid biopsies +	(Intercept)	-0.47
MRI features	Liquid biopsies model	0.67
post- treatment	Computer extracted MRI features model	0.71
Clinical	(Intercept)	-0.55
radiological + liquid	Clinical-radiological model	0.94
biopsies +	Liquid biopsies model	0.50
MRI features	Computer extracted MRI features model	0
treatment		
Only clinical model	(Intercept)	1.55
model	IHC subtype ER-/HER2-	-0.85
	IHC subtype ER+-/HER2+	-0.88
	Grade 3	-0.59
	Nodal status	0.96
Only clinical	(Intercept)	-0.02
+ liquid biopsies pre-	Only clinical model	1.02
treatment	Liquid biopsies model	0
Only clinical	(Intercept)	-0.02
+ MRI features pre-	Only clinical model	1.02
treatment	Computer extracted MRI features model	0
Only clinical	(Intercent)	0.02
+ MRI features +	(Intercept)	-0.02
liquid	Only clinical model	1.02
biopsies pre- treatment	Liquid biopsies model	0
	Computer extracted MRI features model	0
Only clinical + liquid	(Intercept)	-0.61
biopsies on-	Only clinical model	0.93
treatment	Liquid biopsies model	0.55
	Liquiu biopsies Hibuei	0.55

Only clinical + MRI	(Intercept)	-0.75
features on-	Only clinical model	0.83
treatment	Computer extracted MRI features model	0.76
Only clinical + MRI	(Intercept)	-1.08
features +	Only clinical model	0.80
liquid biopsies on-	Liquid biopsies model	0.39
treatment	Computer extracted MRI features model	0.68
Only clinical + liquid	(Intercept)	-0.62
biopsies post-	Only clinical model	0.82
treatment	Liquid biopsies model	0.67
Only clinical + MRI	(Intercept)	-0.59
features post-	Only clinical model	0.82
treatment	Computer extracted MRI features model	0.66
Only clinical	(Intercept)	-0.81
features +	Only clinical model	0.76
liquid biopsies post-	Liquid biopsies model	0.53
treatment	Computer extracted MRI features model	0.36